For your patients aged 6 years and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable

You may have patients aged 6 years and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or for whom those therapies are not advisable. DUPIXENT® may be an appropriate choice for these patients. DUPIXENT® can be used with or without topical corticosteroids.1

See examples of patients who might be appropriate for DUPIXENT®

I

Michael*

Clinical Profile

• 50 years old
• Diagnosed with moderate-to-severe AD in early childhood
• Lacks disease control with TCS
• Current Tx: CsA

Impact

• Chronic lesions with lichenification
• Persistent severe itch

Michael’s Treatment Goals

• Reduce itching
• Heal skin lesions
• Improve his quality of life

* Not actual patient. May not be representative of all patients.

I

Shannon*

Clinical Profile

• 26 years old
• Diagnosed with moderate-to-severe AD in early childhood
• Experienced troublesome lesions
• Inadequately controlled with current Tx
• Current Tx: TCS

Impact

• Sore lesions on the neck and hands
• Frequent itch

Shannon’s Treatment Goals

• Reduce itching
• Reduce severity of skin lesions
• Improve her quality of life

* Not actual patient. May not be representative of all patients.

I

George*

Clinical Profile

• 16 years old
• Diagnosed with moderate-to-severe AD 8 years ago
• Experiencing intense signs and symptoms
• Lacks disease control with current Tx
• Current Tx: TCS

Impact

• Highly visible lesions on face
• Distracting itch
• Affects his quality of life

George’s Treatment Goals

• Reduce itching
• Reduce severity of skin lesions
• Improve his quality of life

* Not actual patient. May not be representative of all patients.

I

Marie*

Clinical Profile

• 8 years old
• Diagnosed with moderate-to-severe AD at age 3
• Chronic lesions on face and body
• Persistent itch
• Lacks disease control with current Tx

• Current Tx: medium-to-high potency topical corticosteroids and topical calcineurin inhibitors

Impact

• Distracting itch affects her quality of life
• Her parents report that Marie has difficulty controlling  the urge to scratch
• Marie’s parents worry about the impact AD has on their daughter’s quality of life

Marie’s Treatment Goals

• Reduce itching
• Favourable changes in quality of life
• Find a treatment that has a longer-term safety profile available in children

* Not actual patient. May not be representative of all patients.


TCS: topical corticosteroids; Tx: treatment; CsA: Cyclosporin A

Dosing and Administration

Thinking about prescribing DUPIXENT®? Find helpful information to get started.

Frequently Asked Questions

Have questions? Get answers to some of the most commonly asked questions.



DUPIXENT®, Sanofi and Freedom logos are trademarks of Sanofi, used under license by sanofi-aventis Canada Inc.
REGENERON® is a trademark of Regeneron Pharmaceuticals, Inc. All rights reserved.
© 2023 sanofi-aventis Canada Inc. All rights reserved.

MAT-CA-2300298
Last updated: 06/2023

paab logo